J. L. Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. L. Davis has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A. Curling
Department of Clinical Sciences College of Veterinary Medicine North Carolina State University Raleigh NC USA
1 shared publication- Anthony T. Blikslager
Department of Clinical Sciences North Carolina State University Raleigh North Carolina USA
1 shared publication B. Holland
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA
1 shared publicationB. M. Barlow
Department of Clinical Sciences College of Veterinary Medicine North Carolina State University Raleigh NC USA
1 shared publicationC. J. Alcott
Department of Veterinary Clinical Sciences Lloyd Veterinary Medical Center College of Veterinary Medicine Iowa State University Ames IA USA
1 shared publication- Callie A. Fogle
Department of Veterinary Medical Sciences, College of Veterinary Medicine, Clemson University, Clemson, SC
1 shared publication
Latest Publications
- 8 September 2015
- Published by Wiley in Equine Veterinary Education
- Vol. 29 (2) , 104-113
Nonsteroidal anti‐inflammatory drug associated right dorsal colitis in the horse
Summary: Right dorsal colitis in horses is a disease characterised by mucosal ulceration and oedema that is localised to the right dorsal colon. It is considered one of the more severe adverse effects associated with the use of nonsteroidal anti‐inflammatory drugs ( NSAID s), particularly phenylbutazone. Diagnosis is typically made based on a history of NSAID administration, the presence of hypoproteinaemia and hypoalbuminaemia, as well as ultrasound evidence of thickening and oedema of the right dorsal colon wall. Definitive diagnosis is made at surgery or necropsy. Treatment involves discontinuation of NSAID therapy, dietary management, and mucosal protectants such as misoprostol and sucralfate. Prognosis is dependent upon early recognition and appropriate treatment. Horses on prolonged courses of NSAID s should have frequent monitoring of serum total protein and albumin concentrations, as this is one of the earliest and most consistent clinicopathological findings.
- 8 September 2015
- Published by Wiley in Equine Veterinary Education
- Vol. 29 (2) , 104-113
Nonsteroidal anti‐inflammatory drug associated right dorsal colitis in the horse
Summary: Right dorsal colitis in horses is a disease characterised by mucosal ulceration and oedema that is localised to the right dorsal colon. It is considered one of the more severe adverse effects associated with the use of nonsteroidal anti‐inflammatory drugs ( NSAID s), particularly phenylbutazone. Diagnosis is typically made based on a history of NSAID administration, the presence of hypoproteinaemia and hypoalbuminaemia, as well as ultrasound evidence of thickening and oedema of the right dorsal colon wall. Definitive diagnosis is made at surgery or necropsy. Treatment involves discontinuation of NSAID therapy, dietary management, and mucosal protectants such as misoprostol and sucralfate. Prognosis is dependent upon early recognition and appropriate treatment. Horses on prolonged courses of NSAID s should have frequent monitoring of serum total protein and albumin concentrations, as this is one of the earliest and most consistent clinicopathological findings.
- 27 November 2014
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 38 (3) , 301-304
Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares
The objective of this study was to evaluate the pharmacokinetic properties and physiologic effects of a single oral dose of alprazolam in horses. Seven adult female horses received an oral administration of alprazolam at a dosage of 0.04 mg/kg body weight. Blood samples were collected at various time points and assayed for alprazolam and its metabolite,α‐hydroxyalprazolam, using liquid chromatography/mass spectrometry. Pharmacokinetic disposition of alprazolam was analyzed by a one‐compartmental approach. Mean plasma pharmacokinetic parameters (±SD) following single‐dose administration of alprazolam were as follows: Cmax14.76 ± 3.72 ng/mL and area under the curve (AUC0–∞) 358.77 ± 76.26 ng·h/mL. Median (range) Tmaxwas 3 h (1–12 h). Alpha‐hydroxyalprazolam concentrations were detected in each horse, although concentrations were low (Cmax1.36 ± 0.28 ng/mL). Repeat physical examinations and assessment of the degree of sedation and ataxia were performed every 12 h to evaluate for adverse effects. Oral alprazolam tablets were absorbed in adult horses and no clinically relevant adverse events were observed. Further evaluation of repeated dosing and safety of administration of alprazolam to horses is warranted.
- 27 November 2014
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 38 (3) , 301-304
Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares
The objective of this study was to evaluate the pharmacokinetic properties and physiologic effects of a single oral dose of alprazolam in horses. Seven adult female horses received an oral administration of alprazolam at a dosage of 0.04 mg/kg body weight. Blood samples were collected at various time points and assayed for alprazolam and its metabolite,α‐hydroxyalprazolam, using liquid chromatography/mass spectrometry. Pharmacokinetic disposition of alprazolam was analyzed by a one‐compartmental approach. Mean plasma pharmacokinetic parameters (±SD) following single‐dose administration of alprazolam were as follows: Cmax14.76 ± 3.72 ng/mL and area under the curve (AUC0–∞) 358.77 ± 76.26 ng·h/mL. Median (range) Tmaxwas 3 h (1–12 h). Alpha‐hydroxyalprazolam concentrations were detected in each horse, although concentrations were low (Cmax1.36 ± 0.28 ng/mL). Repeat physical examinations and assessment of the degree of sedation and ataxia were performed every 12 h to evaluate for adverse effects. Oral alprazolam tablets were absorbed in adult horses and no clinically relevant adverse events were observed. Further evaluation of repeated dosing and safety of administration of alprazolam to horses is warranted.
- 5 November 2014
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 38 (3) , 249-256
Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses
The objectives of this study were to compare the pharmacokinetics and COX selectivity of three commercially available formulations of firocoxib in the horse. Six healthy adult horses were administered a single dose of 57 mg intravenous, oral paste or oral tablet firocoxib in a three‐way, randomized, crossover design. Blood was collected at predetermined times for PGE2 and TXB2 concentrations, as well as plasma drug concentrations. Similar to other reports, firocoxib exhibited a long elimination half‐life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg). Comparison of the oral formulations revealed a higher Cmax, shorter Tmax, and greater AUC for the paste compared to the tablet. Bioavailability was 112% and 88% for the paste and tablet, respectively. Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation. Pharmacodynamic modeling suggests an IC50 of approximately 27 ng/mL and an IC80 of 108 ng/ mL for COX2 inhibition. Inhibition of TXB2 production was not detected. This study indicates a lack of bioequivalence between the oral formulations of firocoxib when administered as a single dose to healthy horses.
- 5 November 2014
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 38 (3) , 249-256
Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses
The objectives of this study were to compare the pharmacokinetics and COX selectivity of three commercially available formulations of firocoxib in the horse. Six healthy adult horses were administered a single dose of 57 mg intravenous, oral paste or oral tablet firocoxib in a three‐way, randomized, crossover design. Blood was collected at predetermined times for PGE2 and TXB2 concentrations, as well as plasma drug concentrations. Similar to other reports, firocoxib exhibited a long elimination half‐life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg). Comparison of the oral formulations revealed a higher Cmax, shorter Tmax, and greater AUC for the paste compared to the tablet. Bioavailability was 112% and 88% for the paste and tablet, respectively. Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation. Pharmacodynamic modeling suggests an IC50 of approximately 27 ng/mL and an IC80 of 108 ng/ mL for COX2 inhibition. Inhibition of TXB2 production was not detected. This study indicates a lack of bioequivalence between the oral formulations of firocoxib when administered as a single dose to healthy horses.
- 8 October 2013
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 37 (3) , 243-251
Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals
The purpose of this study was to determine the pharmacokinetics and safety profile of firocoxib in neonatal foals. Seven healthy foals were administered 0.1 mg/kg firocoxib orally q24 h for nine consecutive days, commencing at 36 h of age. Blood was collected for firocoxib analysis using high‐pressure liquid chromatography with fluorescence detection at 0 (dose #1 only), 0.25, 0.5, 1, 2, 4, 8, 16, and 24 h after doses 1, 5, and 9. For all other doses (2, 3, 4, 6, 7, and 8), blood was collected immediately prior to the next dose (24 h trough). Elimination samples (36, 48, 72, 96, 120, and 144 h) were collected after dose 9. Safety was assessed via physical examinations, body weight measurements, gastroscopy, complete blood count, plasma biochemistry and urinalysis. Firocoxib was rapidly absorbed following oral administration with minimal accumulation after repeat dosing. After the final dose, the terminal half‐life was approximately 11 h. Firocoxib was below the limit of detection (<2.5 ng/mL) in plasma 72 h after the final dose. No significant abnormalities were found on blood analyses, urinalysis, or gastroscopy. This study demonstrated that firocoxib is absorbed in neonatal foals with no demonstrable adverse effects after repeated doses of 0.1 mg/kg.
- 8 October 2013
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 37 (3) , 243-251
Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals
The purpose of this study was to determine the pharmacokinetics and safety profile of firocoxib in neonatal foals. Seven healthy foals were administered 0.1 mg/kg firocoxib orally q24 h for nine consecutive days, commencing at 36 h of age. Blood was collected for firocoxib analysis using high‐pressure liquid chromatography with fluorescence detection at 0 (dose #1 only), 0.25, 0.5, 1, 2, 4, 8, 16, and 24 h after doses 1, 5, and 9. For all other doses (2, 3, 4, 6, 7, and 8), blood was collected immediately prior to the next dose (24 h trough). Elimination samples (36, 48, 72, 96, 120, and 144 h) were collected after dose 9. Safety was assessed via physical examinations, body weight measurements, gastroscopy, complete blood count, plasma biochemistry and urinalysis. Firocoxib was rapidly absorbed following oral administration with minimal accumulation after repeat dosing. After the final dose, the terminal half‐life was approximately 11 h. Firocoxib was below the limit of detection (<2.5 ng/mL) in plasma 72 h after the final dose. No significant abnormalities were found on blood analyses, urinalysis, or gastroscopy. This study demonstrated that firocoxib is absorbed in neonatal foals with no demonstrable adverse effects after repeated doses of 0.1 mg/kg.
- 12 March 2013
- Published by Wiley in Equine Veterinary Education
- Vol. 25 (5) , 247-255
Management and complications associated with treatment of cervical oesophageal perforations in horses
Summary: Six horses were evaluated for colic and anorexia, choke or suspected oesophageal rupture with and without tracheal laceration. Clinical findings were variable, but a painful ventral neck swelling was noted in all cases. Two of the horses had signs of dehydration and sepsis. Additional findings included evidence of previous trauma over the trachea and oesophagus, ventral neck abscessation, choke and aspiration pneumonia. A diagnosis of oesophageal perforation was made using endoscopy. Two horses were subjected to euthanasia without treatment. All horses where treatment was attempted received debridement of the oesophageal perforation and surrounding tissues with or without surgical closure of the oesophageal defect. Other therapies included broad spectrum antimicrobials, anti‐inflammatory drugs, fluid and nutritional support as well as additional therapeutics for sepsis and individual complications. Complications included diverticulum formation, thrombophlebitis, diarrhoea, laryngeal hemiplegia, azotaemia, aspiration pneumonia, oesophageal obstruction, weight loss and laminitis. All 4 treated horses recovered from the oesophageal perforation and are able to eat a normal diet. Two of the 4 horses have had infrequent episodes of recurrent choke. Oesophageal rupture should be considered as a differential diagnosis for horses with a painful swelling of the ventral neck. With surgical debridement and adequate supportive care, oesophageal perforation cases can have a fair to good long‐term survival, although chronic complications can occur, therapy is prolonged, and a significant economic commitment is required.
- 12 March 2013
- Published by Wiley in Equine Veterinary Education
- Vol. 25 (5) , 247-255
Management and complications associated with treatment of cervical oesophageal perforations in horses
Summary: Six horses were evaluated for colic and anorexia, choke or suspected oesophageal rupture with and without tracheal laceration. Clinical findings were variable, but a painful ventral neck swelling was noted in all cases. Two of the horses had signs of dehydration and sepsis. Additional findings included evidence of previous trauma over the trachea and oesophagus, ventral neck abscessation, choke and aspiration pneumonia. A diagnosis of oesophageal perforation was made using endoscopy. Two horses were subjected to euthanasia without treatment. All horses where treatment was attempted received debridement of the oesophageal perforation and surrounding tissues with or without surgical closure of the oesophageal defect. Other therapies included broad spectrum antimicrobials, anti‐inflammatory drugs, fluid and nutritional support as well as additional therapeutics for sepsis and individual complications. Complications included diverticulum formation, thrombophlebitis, diarrhoea, laryngeal hemiplegia, azotaemia, aspiration pneumonia, oesophageal obstruction, weight loss and laminitis. All 4 treated horses recovered from the oesophageal perforation and are able to eat a normal diet. Two of the 4 horses have had infrequent episodes of recurrent choke. Oesophageal rupture should be considered as a differential diagnosis for horses with a painful swelling of the ventral neck. With surgical debridement and adequate supportive care, oesophageal perforation cases can have a fair to good long‐term survival, although chronic complications can occur, therapy is prolonged, and a significant economic commitment is required.
- 21 May 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 36 (1) , 99-101
Pharmacokinetics of a continuous rate infusion of ceftiofur sodium in normal foals
- 21 May 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 36 (1) , 99-101
Pharmacokinetics of a continuous rate infusion of ceftiofur sodium in normal foals